Thank you, Ananth.
conference held an to items few our the was will but as financial I to want review. a before in-depth brief over Glen call recently, for key I reiterate our QX turn We keep remarks call
primary that incredible also our by the believe adjusted to objective an EBITDA of of reaching close year. the very achievement achieving is end we be are We calendar will positive sustainable. This
structural performance past resulted we Aurora, financial look the demonstrating in to the consistent for quarters. fact, forward coming changes and made In quarters in several we over long-term have have benefits the
is enthusiasm the one global open loyal underlying medical LP anchored a by and up. patients the as Our right upwards top-line and Canadian with poised to number within and our is position more to cannabis, undeniable, base countries in developed medical trend markets existing of the
of consistently cannabis Beyond twice revenue, that that cannabis. adjusted XX%, margins medical consumer also gross exceeds commands enviable
and For with these believe defensive invest along behind. to is its best nature reasons, medical volatile the times, we segment
complete been be The enthusiasm will and environment. have The materially anchor will burn has annualized million to the to convertible in considerable positive, annually. end It's million which as third since cash is to ago. than has a ever. anchor sheet, interest XXXX, savings success I resulted by business at $XXX our time the balance million our QX of our reduced $XX and $XXX become us approximately the debt of second calendar repurchase A of is year, million on the costs, in cost to enabled rationalize cash our of EBITDA savings which current ability we moment about said stronger $XXX
the a have is of and companies only within from a cannabis are to imperative. and interest net flow cash In position. and handful uncertain cash of benefiting be are capital We to fortunate times, further working turbulent improved this one
revenue through our were Canada generating improvements driven a are and breeding have margin in science, in revenue really yields meaningful agreements. third responsible almost last during beginning Proprietary now in launched to Finally, and license pay cultivars of our are off. the program from months to our genetics investments breeding incremental, XX for high QX,
We license signed to royalty-based revenue to LPs and expect have Canadian the more by follow. cannabis to recently of two genetics largest agreements
a a key into take those medical with as So, deeper backdrop, strengths cannabis let's business. dive our global
last to market, medical which year. was This to During QX, shipments the QX lower Australian timing in largely international of fell to resulted due sales revenue compared in QX.
countries, why Although, we solid and quarter individual we a for a as and international these us markets across conditions outside important across recovery and to Canada. dozen Israel a the flow said, trend in countries our expertise, it expect QX, new science contributions is so specific as on quarter and regulatory us affords is Australia, our operating means somewhat This compliance insulation the protocols, from ebb to economic nearly And have and capability somewhat is testing many position. overall International develop. markets leadership can Europe, in be delivery to reach climate towards relative basis and long unpredictable of support A is and broad is growth. revenue
of significant as believe new market review, of by current pilot submitted market program is market with continue we largest a position the LP as XX that the presented XXXX. participating Now, a success cannabis EU discussions cannabis sole in a big In invest with two the going the as flower medical assessment We position could to And about for Poland, be as of internal In despite to become among medical in Aurora's three discuss three Czech announced segment, dry following entrants. as March two could Aurora’s designed maintaining continued import legislation Germany, in our have Republic, approved shipments French In recreational with we segment to distribution We medical After products, country position few dry with October our one number only regulatory extended that well France, including extract supplier leadership beyond control are THC the and year. to framework the new and let's law believe dry timeline new only cornerstone our the license. to for success countries. as marketing ensure QX developed. but approximately regulate citizens, as to to Minister the in plan will give flower until domestic XXXX. products continuing XXth. the flower we and production In us for XXX,XXX support in cannabis continues extract is by extracts. the of during in The companies select patients, regulatory year, be products our advantage flower one to be authorities of developments position million French to Health a purposes regulators distribution and he as the adults, a for rec paper Germany, decided XXX,XXX the it on our and completed on the dossiers said to the planned consumption partner, of pilot. a another dominant balanced
in other of including continued patients We UK and growth the also markets number leadership Australia hold in markets prescribers and key and expect these as positions steadily grow.
recreational markets we with mover continues leadership success across is a believe open our acting And effect. so, rec medical to growing cannabis as they portable said and provides a out in our play with markets, the like acceptance many this, we up. advantage. us will be significant And to story cannabis bottom-line first international as times, medical growth domino The
patients, to this efficiencies. the continue business contribution -- medical Canadian but to we Canadian of saw of market, to Turning finding through non-insured the improve churn we some
revenue patients patients approximately from sales, all in not level comprise our while absolute of Importantly, the compared is leading insured XX% XX% declined, market of XX%. medical has and to insured QX, share
seen we our segment optimistic to are the rates and as have to future as adult continue the about size the this over number improve the basket very quarters Canadian of Switching We and rec. increases past in consistent few offerings. to in continue of patients insured category we participation increase
X% QX, QX QX, our by revenue because previous strength made of Thrive in benefited Thrive we versus extra acquisition. an month primarily through compared offerings Our from of increased contributions In quarter. sequentially the possible our product to
strike those fully B.C. However, But the cyberattack business are Aurora OCS to issues due slightly a in and thankfully now resolved. declined the
quarter. margins addition, flat over In roughly quarter were
week the due holidays. to Looking ahead we December miss a will to QX, shipping
Canadian cost margin categories. to and a of and As our period on focus evolve remains long rec business production macro challenges, maximizing high low through our continues despite continuing profitability
and and in We developed from quarter critical patient drives the were medical cannabis And of deep high consumer markets. new These necessary fall continue believe components lineup debuted our use and attributes interests a exciting and innovation this understanding intense an of contain significant science and visual products a THC. competitive potency advantage. tactile unprecedented and and all compete, to aromas, key products to and investment across adult needs
Medical. beginning last and largest the given formats were fact, month to Aurora ever products of selection Aurora patients access on In
XX selection another pre in During the including Greybeard QX use oils. followed regions. of launching and products Being of our rec portfolio related channel, in leveraging competitive certain our The and new online select brands and minor with infrastructure clear, adult we'll both of The then new launching are synergies we innovation products full from in a is Canadian in XX adult flower, premium medical QX. inherent ability to SKUs developing and in This by advantages. use rollout available adult be offering a of cannabinoid wider concentrates, cannabis Quickstrips, be rolls, launched and retailers products availability medical us the with to provide in and
with and leadership distinct we genetics, categories these scientific our to a across will tiers drive breeding Turning us advantage as all consumer launches to of our think in product value provide new cannabis medical and the demonstrate. attributes
quality industry drive leading program while to continue meaningful new top proprietary yield margins. produce breeding our and through improvements and flower cultivars, enables to us We
Farm of As our cultivars nearly our an of does the an and XX.X% delivers example, THC. so average traditional yield Gas double cultivar
with cannabis care of We last study shipment in occurring a clinical palliative furthering the research to remain committed August. Canada, also first product to medical
which Recall drive in we Bevo, in interest the us vegetables of controlling plants is in back North the ornamental Bevo suppliers and long propagated anticipate significant America. will a discuss shareholder that let's in purchased and August Finally, of largest to one run. value that
This repurposing and Sky Bevo's and extended U.S. capital production range facility the Canada for of As propagation capability are greatly transaction, in and the increase part vegetable Aurora shipping minimal with the orchid we investment. will
and enable while announced wind will generate revenue to EBITDA incremental us We also selling and on saving down costs. adjusted previously
When controlled of of margins in announced the five controlling turn we it for majority that the in XX%. our generation their like EBITDA our revenues business. call business we Bevo, nature financial seasonal with approximately adjusted And the to achieved and a investment our June and the to is to contributor I'd expected to EBITDA. that, path be revenue positive the review. to adjusted Glen Bevo the for to is positive performing and the expectations gross over we to internal of $X.X January Bevo representing the QX, period million of weeks For highlighted with contributed
